Loading clinical trials...
Loading clinical trials...
The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in participants with non-cystic fibrosis bronchiectasis.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Insmed Incorporated
NCT07289464 · Non-cystic Fibrosis Bronchiectasis
NCT07608328 · Non-cystic Fibrosis Bronchiectasis, Bronchiectasis Adult, and more
NCT04594369 · Non-Cystic Fibrosis Bronchiectasis
NCT06237348 · Non-cystic Fibrosis Bronchiectasis, Chronic Mucus Hypersecretion
NCT04656275 · Non-cystic Fibrosis Bronchiectasis
University of Alabama at Birmingham
Birmingham, Alabama
Phoenix Medical Group
Peoria, Arizona
NewportNativeMD
Newport Beach, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions